Sponsors (10)
This bill restores prior Medicaid and orphan-drug rules to avoid implementation disruption and preserve access for vulnerable patients, at the cost of foregone savings from price negotiation and potential budget and planning disruptions for states, providers, and federal programs.
Medicaid beneficiaries (low-income individuals and families) keep prior eligibility and benefit rules, preventing sudden loss of coverage or benefits.
State governments, hospitals/health systems, and HHS avoid new implementation and transition costs and confusion by reverting to the prior legal baseline.
Taxpayers face lower near-term federal outlays because appropriations tied to the repealed changes are rescinded.
State governments and hospitals/health systems that had planned programs or relied on new authorities may face funding shortfalls or operational disruption if those changes are reversed.
Medicaid beneficiaries could experience uncertainty or delays in access if planned program changes, expansions, or new services are canceled or postponed.
Medicare beneficiaries and taxpayers may face higher drug spending because orphan drugs remain excluded from price negotiation, which can keep prices elevated and put upward pressure on premiums and federal budgets.
Based on analysis of 3 sections of legislative text.
Reverses two specific amendments from Public Law 119–21, restoring prior Medicaid law and the prior orphan‑drug exclusion for drug price negotiation and rescinding related appropriations.
Restores prior law by removing two provisions added by Public Law 119–21: it cancels the specific Medicaid amendment and associated funding added earlier and it reverses the change to the Drug Price Negotiation Program’s orphan‑drug exclusion, making the law read as if those two provisions were never enacted. The bill also rescinds the appropriated amounts tied to the Medicaid provision it removes. The effect is to roll back those targeted adjustments to title XIX (Medicaid) and title XI (drug price negotiation/orphan‑drug treatment) of the Social Security Act, returning statutory text and funding status to the pre‑Public Law 119–21 state.
Official title: To repeal changes to Medicaid cost sharing requirements and the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program.
Introduced September 2, 2025 by Chris Pappas · Last progress September 2, 2025